SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as a community-driven project aiming to replicate the massive growth of previous viral memecoins through active social media raiding and a transparent developer-led approach. While the community is currently focused on overcoming technical hurdles like securing official charts and listings, members are heavily incentivized by the potential for 1000x gains and a movement-based ethos that rejects typical 'pump and dump' behavior.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is attracting significant community attention as traders debate its potential for a breakout, with many highlighting the upcoming Layla upgrade in May 2026 as a pivotal catalyst for increased utility and quantum resistance. While bulls point to resilient price action and the network's low-fee, peer-to-peer focus, ongoing discussions remain polarized between those expecting a major decoupling from Bitcoin and critics dismissing the asset due to historical performance concerns.

Nucor Corp. engages in the manufacture of steel products, and ferrous and non-ferrous materials. It operates through the following segments: Steel Mills, Steel Products, and Raw Materials. The Steel Mills segment consists of producing sheet, plate, structural, and bar steel. The Steel Products segment includes steel joists and joist girders, deck, fabricated concrete reinforcing, cold finished, fasteners, metal building systems, grating, tubular, piling products businesses, and wire mesh. The Raw Materials segment consists of direct reduced iron, and ferrous and nonferrous metals. The company was founded by Ransom E. Olds in 1905 and is headquartered in Charlotte, NC.

Nucor Corp.

Nucor is trending as investors react to the anticipated formalization of 25% tariffs on global steel and aluminum imports. The community is actively discussing how these protective measures may bolster domestic manufacturing demand and pricing power, with some participants expressing caution regarding potential inflationary impacts and global trade volatility.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to heightened investor focus on the upcoming PDUFA decision date for RP1, with market participants debating whether the resubmission successfully addresses previous FDA concerns or if a second Complete Response Letter is likely. The community remains deeply divided, with some traders citing unusual options volume and potential short-covering as bullish indicators, while skeptics warn of significant downside risk if the company fails to secure accelerated approval.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is capturing significant investor attention as markets weigh the company's ambitious 2026 profitability guidance against its recent quarterly earnings miss. While the community remains deeply divided between those betting on long-term growth through AI-driven operational efficiency and skeptics concerned about medical loss ratios, retail traders are closely tracking the stock's volatility ahead of potential structural pivots in the healthcare sector.

SiriusXM Holdings, Inc. engages in the provision of audio entertainment. It operates through the Sirius XM and Pandora and Off-Platform segments. The Sirius XM segment features a wide range of content, including, music, sports, entertainment, comedy, talk and news channels, podcasts and infotainment services, all available in the United States on a subscription fee basis. The Pandora and Off-Platform segment generates a majority of its revenues from third parties advertising on the Pandora ad-supported service and other platforms. The company was founded on May 17, 1990, and is headquartered in New York, NY.

Sirius XM Holdings Inc.

Sirius XM Holdings Inc

Sirius XM Holdings is attracting intense investor attention as Berkshire Hathaway continues to aggressively increase its stake, signaling strong institutional confidence despite recent downward price pressure. The community is actively debating the company's valuation, dividend stability, and the potential impact of high short interest amid ongoing speculation regarding future content strategies and M&A activity.

Invesco DB US Dollar Index Bullish Fund - Common units of beneficial interest

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund is trending as market participants weigh conflicting signals between safe-haven demand amid rising Middle East geopolitical tensions and concerns over long-term fiscal deficits. Traders are actively debating the dollar's strength relative to precious metals and foreign currencies as they monitor key labor data and shifting central bank interest rate policies.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is seeing increased investor attention as the company leverages a robust pipeline, including recent label expansions and the continued development of its oncology portfolio, to navigate patent cliffs. Market sentiment is bolstered by steady dividends and strategic collaborations, though traders remain focused on upcoming trial data readouts that will be critical for long-term growth and potential M&A activity.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending due to surging after-hours volume and unconfirmed speculation regarding a potential buyout, which has intensified community discussion about its valuation and long-term pipeline potential. Investors are closely monitoring unusual block trades and technical price action, viewing these signals as potential precursors to an M&A event despite historical skepticism regarding the company's independence.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is currently generating intense debate among retail traders, with many participants expressing extreme bearish sentiment and anticipation of further downward price movement. The community remains deeply divided, with vocal skeptics labeling the project a "ghost chain" while contrarian traders continue to monitor support levels in search of potential re-entry points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

Bausch Health to Announce First Quarter 2026 Results on April 29, 2026 Bausch Health to Announce First Quarter 2026 Results on April 29, 2026 PR Newswire LAVAL, QC, March 31, 2026 LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter...

Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Recommendation of "Reduce" by Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) have been given a consensus rating of "Reduce" by the five analysts that are covering the stock, Marketbeat Ratings reports. One equities...

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program PR Newswire LAVAL, QC, March 26...

Is the Options Market Predicting a Spike in Bausch Health Stock?

Investors need to pay close attention to BHC stock based on the movements in the options market lately.

Bausch (BHC) Down 15.2% Since Last Earnings Report: Can It Rebound?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch Health Cos Inc. $BHC is Goldentree Asset Management LP's Largest Position

Goldentree Asset Management LP lifted its holdings in Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 1.7% in the third quarter, according to its most recent disclosure with the SEC. The...

Bausch Health Cos Inc. $BHC Shares Sold by Compass Rose Asset Management LP

Compass Rose Asset Management LP cut its stake in shares of Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 50.0% in the 3rd quarter, according to its most recent filing with the Securities...

Q2 EPS Forecast for Bausch Health Cos Decreased by Analyst

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Equities research analysts at Zacks Research decreased their Q2 2027 earnings estimates for Bausch Health Cos in a research note issued on Wednesday...

Zacks Research Issues Positive Estimate for TSE:BHC Earnings

Bausch Health Companies Inc. (TSE:BHC - Free Report) - Stock analysts at Zacks Research upped their Q2 2026 EPS estimates for shares of Bausch Health Companies in a report issued on Wednesday, March...

Zacks Research Expects Lower Earnings for Bausch Health Cos

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Investment analysts at Zacks Research decreased their Q1 2026 earnings per share estimates for Bausch Health Cos in a report issued on Wednesday...

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch Health Companies Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

BHC
Bausch Health Companies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BHC News

BHCBausch Health Companies Inc